Title Physician

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

NCT ID : 04291105
Phase : 2
Location : Santa Monica, CA
Dr. O'Day

Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherapy, vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)

NCT ID : 04223856
Phase : 3
Location : Santa Monica, CA
Dr. Twardowski

Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)

NCT ID : 04186845
Phase : 3
Location : Santa Monica, CA
Dr. Twardowski and Dr. Hanelin

⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

NCT ID : 03802123
Phase : 2
Location : Santa Monica, CA
Dr. O'Day

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer

NCT ID : 04186819
Phase : 3
Location : Santa Monica, CA
Dr. Twardowski and Dr. Hanelin

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT ID : 03170960
Phase : 1 and 2
Location : Santa Monica, CA
Dr. Twardowski

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905)

NCT ID : 03924895
Phase : 3
Location : Santa Monica, CA
Dr. Twardowski

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

NCT ID : 03924856
Phase : 3
Location : Santa Monica, CA
Dr. Twardowski

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy

NCT ID : 03898180
Protocol Number : MK-7902-011
Phase : 3
Location : Santa Monica, CA
Dr. Twardowski

A Phase I Study of AGEN1181, an Fe-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

NCT ID : 03860272
Protocol Number : C-800-01
Phase : 1
Location : Santa Monica, CA
Dr. O'Day

Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

NCT ID : 03684785
Protocol Number : AST-008-102
Phase : 1b/2
Location : Santa Monica, CA
Dr. O'Day

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT ID : 03633110
Protocol Number : GEN-009-101
Phase : 1 and 2
Location : Santa Monica, CA
Dr. Twardowski

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Camette-Guerin (BCG) Therapy

NCT ID : 02625961
Protocol Number : MK-3475-057 (20160487)
Phase : II
Location : Santa Monica, CA
Dr. Wilson